{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:21:30Z","timestamp":1791321690760,"version":"4.3.1"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"5","license":[{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Paratek Pharmaceuticals"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,4,21]]},"abstract":"<jats:p>Omadacycline is a broad-spectrum aminomethylcycline approved in October 2018 by the U.S. Food and Drug Administration for treating acute bacterial skin and skin structure infections and community-acquired pneumonia as both an oral and intravenous once-daily formulation. In this report, the activities of omadacycline and comparators were tested against 49,000 nonduplicate bacterial isolates collected prospectively during 2016 to 2018 from medical centers in Europe (24,500 isolates, 40 medical centers [19 countries]) and the United States (24,500 isolates, 33 medical centers [23 states and all 9 U.<\/jats:p>","DOI":"10.1128\/aac.02488-19","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T13:31:53Z","timestamp":1581514313000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":59,"title":["Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018"],"prefix":"10.1128","volume":"64","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"University of Iowa, Iowa City, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/s1368-7646(02)00051-1"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/367622"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz394"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a025387"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz395"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1900188"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01536-15"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-13"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800170"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800201"},{"key":"e_1_3_2_16_2","unstructured":"ClincalTrials.gov. 2017. Oral omadacycline vs. oral nitrofurantoin for the treatment of cystitis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03425396. Accessed June 2018."},{"key":"e_1_3_2_17_2","unstructured":"ClinicalTrials.gov. 2018. IV or IV\/PO omadacycline vs. IV\/PO levofloxacin for the treatment of acute pyelonephritis. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03757234. Accessed June 2018."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2015.12.002"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000182"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)00065-7"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy346"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02262-18"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.02.017"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-16"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.010"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.01.019"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02058-19"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00624-19"},{"key":"e_1_3_2_32_2","volume-title":"Abstr European Congress of Clinical Microbiology and Infectious Disease (ECCMID)","author":"Bhavnani SM","year":"2019","unstructured":"Bhavnani SM, Hammel JP, Lakota EA, Liolios K, Rubino CM, Steenbergen JN, Friedrich L, Tzanis E, Ambrose PA. 2019. Assessment of pharmacokinetics-pharmacodynamics to support omadacyline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI), abstr P1944. Abstr European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands."},{"key":"e_1_3_2_33_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. M07Ed11. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_34_2","volume-title":"Performance standards for antimicrobial susceptibility testing: 29th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing: 29th informational supplement. M100Ed29. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_35_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for interpretation of MICs and zone diameters version 9.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf. Accessed January 2019."},{"key":"e_1_3_2_36_2","unstructured":"U.S. Food and Drug Administration. 2018. Recognized antimicrobial susceptibility test interpretive criteria for omadacycline. https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria. Accessed 15 October 2018."},{"key":"e_1_3_2_37_2","unstructured":"Paratek Pharmaceuticals. 2018. Nuzyra TM (omadacycline) package insert. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf. Accessed November 2019."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02488-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02488-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:44:54Z","timestamp":1645479894000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02488-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,21]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,4,21]]}},"alternative-id":["10.1128\/AAC.02488-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02488-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,21]]},"assertion":[{"value":"2019-12-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02488-19"}}